Futibatinib Shows Promise in Breast Cancer With FGFR1 Gene Amplifications
Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.